news
AZD1222 vaccine for COVID-19 is safe and effective in Phase III trials
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19, with no severe cases or hospitalisations reported more than 21 days after first injection.
List view / Grid view
Vaccines
whitepaper
Fact sheet: 5 Secrets to a successful cleaning validation program
Here are five ways to ensure a successful and compliant cleaning validation program.
news
Universal influenza vaccine shows promise in early-phase clinical trial
The chimeric hemagglutinin (HA)-based vaccine induced a strong, functional immune response that lasted at least 18 months.
news
Supply chain challenges cause Pfizer’s COVID-19 vaccine production target to be slashed
Pfizer spokesperson reveals supply chain challenges and late clinical trial results contributed to its COVID-19 vaccine production target for 2020 being halved.
news
Report finds UK Vaccine Taskforce worked “decisively” in fight against COVID-19
An independent review has outlined the achievements of the UK's Vaccine Taskforce, finding it worked "at great pace" to bring a COVID-19 vaccine to patients.
news
First person receives Pfizer and BioNTech COVID-19 vaccine in UK
A 90-year old woman is the first person to receive BNT162b2, the Pfizer and BioNTech COVID-19 vaccine, outside of clinical trials.
news
COVID-19 S-Trimer vaccine candidates show promise in early trials
When adjuvanted with GSK’s pandemic adjuvant system, the S-Trimer vaccine candidates induced the production of neutralising antibodies in all trial participants.
news
Contributing to ACT Accelerator could generate $466 billion for major economies, says Eurasia Group report
The report found that the 10 major economies could see a return of more than $466 billion by 2025, 12 times the total estimated cost of supporting the WHO’s Access to COVID-19 Tools (ACT) Accelerator.
news
EMA begins rolling review of Janssen’s COVID-19 vaccine candidate
The European Medicines Agency's CHMP has started a rolling review of Ad26.COV2.S, Johnson & Johnson's COVID-19 vaccine.
news
COVID-19 vaccines may be less effective for racial minorities, suggest computer scientists
New research suggests that adding extra COVID-19 peptides to a dose of vaccine could increase effectiveness in populations that may not respond robustly to COVID-19 vaccines.
news
Moderna applies for regulatory authorisation for COVID-19 vaccine
The company has submitted for Emergency Use Authorization in the US and Conditional Marketing Authorization in Europe for its mRNA-1273 vaccine against COVID-19.
article
Regulatory response to the COVID-19 pandemic
Dr Ash Ramzan, founder and principal consultant at Woodley BioReg, discusses how the COVID-19 pandemic has forced regulatory processes to adapt, focusing on the regulatory flexibilities introduced by the UK’s MHRA.
news
MHRA approves Pfizer and BioNTech COVID-19 vaccine
The UK's MHRA has given temporary emergency authorisation to Pfizer and BioNTech's COVID-19 vaccine, making it the first in the world to receive approval.
news
Survey finds 64 percent of UK adults would receive COVID-19 vaccine
A survey of 1,500 adults in the UK showed that most would be happy to receive a COVID-19 vaccine, while nine percent said they would be unlikely to get the vaccine.
news
Pfizer and BioNTech submit for EU marketing authorisation for COVID-19 vaccine
If the Conditional Marketing Authorization application is approved, the COVID-19 vaccine BNT162b2 could be used in the EU by the end of 2020.
